Today, UCB held its Annual General Meeting (AGM). During the course of this meeting Roch Doliveux, Chief Executive Officer UCB, gave the shareholders of UCB an overview of the financial year 2009 and the interim report for the first three months of 2010.
“2009 was a pivotal year, marking a new stage in the implementation of our strategy and opening up the way for a new phase of growth. The transformation of UCB into a leading patient-centric bio-pharmaceutical company is coming closer to reality with every day that passes. Our strategic priority to focus on serious diseases of the central nervous system and immunology disorders not only enables us to use our resources effectively but, above all, to build a global reputation for expertise in these fields of science. With the successful launch of three new drugs in the crucial US and/or European markets, we are improving quality of life for a considerable number of people and, at the dawn of a new decade, paving the way for a promising level of growth.
Before outlining UCB’s plans for 2010, I would like to look back at the achievements of the past year and our financial and operating results.
For more information, please click the link below: